Immuno-Oncology – ESMO 2017

OA Dr. Maximilian Hochmair, Otto-Wagner Hospital, Vienna, held a webinar on selected highlights of the treatment of non-small lung cancer (NSCLC) from the ESMO Congress 2017.

Mag. Simone Peter-Ivkić interviewte Prof. Michielin über die Schwerpunkte des ESMO 2017 Kongresses zum Thema "Immuno-Oncology".

Prof. Prager spricht in diesem Video über seine Eindrücke der European Society for Medical Oncology 2017 (ESMO).

Wir interviewten Dr. Curioni auf der ESMO 2017 zu ihren Eindrücken der Veranstaltung und zu den neuesten Forschungsergebnissen.

Univ.-Prof. Dr. Christoph Höller und Ass.-Prof. Priv.-Doz. Dr. Gerald Prager erklären ihre Erkenntnisse rund um das Thema "Melanom".

Chefredakteurin Mag. Simone Peter-Ivkić interviewte Prof. Solange Peters und Dr. Georg Pall bezüglich neuester Entwicklungen zu Lungenkrebs.

Immunotherapy with the checkpoint inhibitor pembrolizumab may be a better option than standard treatments for patients whose head and neck cancer has spread, or recurred after an initial round of chemotherapy.

Excellent news for patients who are at high risk of relapse, according to late-breaking results from the CheckMate 238 trial presented today by Dr Jeffrey Weber.

Results from the KEYNOTE-045 trial have confirmed longer survival in patients with advanced urothelial cancer who receive pembrolizumab.

Here you can find an overview about the abstracts mentioned by Dr. Curioni in her Breakfast Brief video.

Watch Dr. Curioni's update regarding highlight lung cancer studies, presented at the ESMO Congress 2017

Dr. Markus Jörger, Medical oncologist at the Cantonal Hospital in St. Gallen (Switzerland), talks about the importance of tumor agnostics for future cancer drug development.

In this video Dr. Stefan Zimmermann, Hospital Fribourg (Switzerland), talks about the optimal treatment duration with PD-1 inhibitors.

This is our swiss expert with an overview of sunday's Highlights that will be presented at the presidential symposium.